SAN DIEGO, May 10, 2010 (GLOBE NEWSWIRE) -- Harbor Biosciences (Nasdaq:HRBR), a biopharmaceutical company developing novel therapeutics for the treatment of cancer, metabolic and inflammatory diseases, today released an update to its development program for Triolex to treat obesity-induced insulin resistance and type-2 diabetes mellitus (T2DM).
